These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22291080)

  • 1. Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?
    Garrido-Laguna I; Janku F
    J Clin Oncol; 2012 Mar; 30(8):892-3. PubMed ID: 22291080
    [No Abstract]   [Full Text] [Related]  

  • 2. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
    Mita MM; Gong J; Chawla SP
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
    Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
    J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
    Dancey JE; Monzon J
    Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
    Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
    J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ridaforolimus.
    Drugs R D; 2010; 10(3):165-78. PubMed ID: 20945947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of mTOR inhibitors for treatment of sarcomas.
    Mita MM; Tolcher AW
    Curr Oncol Rep; 2007 Jul; 9(4):316-22. PubMed ID: 17588357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for maintenance therapy in managing sarcoma.
    Ray-Coquard I; Le Cesne A
    Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current phase II clinical data for ridaforolimus in cancer.
    Spreafico A; Mackay HJ
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy in the treatment of sarcoma.
    Ray-Coquard I
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):773-4. PubMed ID: 22252579
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
    Frappaz D; Federico SM; Pearson AD; Gore L; Macy ME; DuBois SG; Aerts I; Iannone R; Geschwindt R; Van Schanke A; Wang R; Geoerger B
    Eur J Cancer; 2016 Jul; 62():9-17. PubMed ID: 27185573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An advance in the management of breast cancer].
    Soins; 2013 Apr; (774):12. PubMed ID: 23697050
    [No Abstract]   [Full Text] [Related]  

  • 13. Are we missing the mTOR target in breast cancer?
    Johnston SR
    Breast Cancer Res Treat; 2011 Aug; 128(3):607-11. PubMed ID: 20953834
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
    Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
    Hadji P; Coleman R; Gnant M
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
    Chmielowski B; Federman N; Tap WD
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1217-28. PubMed ID: 23098121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic pipeline for soft-tissue sarcoma.
    Cassier PA; Labidi-Galy SI; Heudel P; Dutour A; Méeus P; Chelghoum M; Alberti L; Ray-Coquard I; Blay JY
    Expert Opin Pharmacother; 2011 Nov; 12(16):2479-91. PubMed ID: 21913865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
    Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
    Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.